Important step forward for Phathom Pharmaceuticals as FDA accepts NDA for new daily heartburn drug 11-Dec-2023 By Liza Laws Millions of US adults suffering from heartburn associated with non-erosive-gastroesophageal-reflux-disease (GERD) could benefit from an impending treatment by Phathom Pharmaceuticals.
FDA promoting innovative clinical trial designs as part of new pilot program 30-Aug-2018 By Melissa Fassbender The FDA has launched a new pilot program targeting complex, innovative clinical trials designs as part of its commitment under PDUFA VI.